Indo US Bio-Tech Ltd
Indo US Bio-Tech Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Indo US Bio-Tech Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for the quarter ended September 30, 2026, is reported as ₹150.483 lakhs.
As stated in Indo US Bio-Tech Ltd's Q2 FY27 results statement · published 30 Oct 2026. Reported figures, not investment advice.
Based on Indo US Bio-Tech Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for the quarter ended September 30, 2026, is reported as ₹150.483 lakhs. Quarterly EBITDA: ₹20.28 crore (Previous Year ₹20.55 crore), slight decrease year-on-year.
From Indo US Bio-Tech Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
How did Indo US Bio-Tech's revenue grow in the September 2026 quarter?
- Revenue from Operations for the quarter ended September 30, 2026, is reported as ₹150.483 lakhs.
- Revenue for the same quarter in the prior year was ₹129.00 lakhs.
- Year-on-year change in revenue is an increase of ₹21.483 lakhs.
What happened to Indo US Bio-Tech's margins in Q2 FY27?
See what Indo US Bio-Tech Ltd said on profitability & margins — free account, 30 seconds.
What capex is Indo US Bio-Tech planning?
2 more points from Indo US Bio-Tech Ltd's call on capex
Create a free account to keep reading this call
Is Indo US Bio-Tech raising money or cutting debt?
See what Indo US Bio-Tech Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Indo US Bio-Tech's order book?
Indo US Bio-Tech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹15 Cr, net loss ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Indo US Bio-Tech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indo US Bio-Tech Ltd Q2 FY27 results?
Revenue from Operations for the quarter ended September 30, 2026, is reported as ₹150.483 lakhs. Quarterly EBITDA: ₹20.28 crore (Previous Year ₹20.55 crore), slight decrease year-on-year.
What is Indo US Bio-Tech Ltd share price analysis?
Indo US Bio-Tech Ltd currently shows a neutral. The stock trades at a P/E of 12.9 with a market cap of ₹147 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indo US Bio-Tech Ltd planning capital expenditure?
The results statement mentions the following capex, capacity expansion, and new project details: - Capital Work-In-Progress (CWIP) increased from ₹50.32 lakhs as of March 31, 2026, to ₹102.85 lakhs as of September 30, 2026, indicating ongoing investment in new assets or expansion. - Purchase of property, plant, and equipment during the half year ended September 30, 2026, was ₹104.77 lakhs. - The company has a Cold Storage and Processing Plant facility located at Village Bardoli Kothi, Indira Nagar, near Cyphon, Ta.
Keep Indo US Bio-Tech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.